Previous Close | 8.19 |
Open | 8.13 |
Bid | 7.85 x 0 |
Ask | 7.86 x 0 |
Day's Range | 7.83 - 8.29 |
52 Week Range | 3.84 - 15.50 |
Volume | |
Avg. Volume | 2,324,111 |
Market Cap | 427.589M |
Beta (5Y Monthly) | 2.59 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -79.20 |
Earnings Date | Jun 12, 2024 - Jun 17, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.83 |
Announced today that it has scheduled a conference call to discuss the results for its fourth quarter ...
Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2024 on Thursday, June 20, 2024 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2024 before the opening of markets that same day.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – the Canadian based leading global medical cannabis company, in conjunction with MedReleaf Australia, is excited to announce the launch of its premium 1.2g resin cartridges in Australia. This expansion marks a significant step in Aurora's mission to provide high-quality products to patients worldwide. Now available for doctors to prescribe to patients in Australia, Aurora's new resign cartridges, developed and manufactured at the company's EU-GMP an